Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15277183 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL9912082 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15944559 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL22096165 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15260697 | 0.99 | CYP3A4 (0.77) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| Hydrochloric Acid SCHEMBL18035153 | 0.99 | CYP3A4 (0.77) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15274560 | 0.99 | CYP3A4 (0.77) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL17329163 | 0.97 | CYP3A4 (0.74) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18035121 | 0.97 | CYP3A4 (0.74) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18035122 | 0.97 | CYP3A4 (0.74) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032718-A1 | CRYSTAL FORM OF HEPATITIS C INHIBITOR AND USE THEREOF IN DRUG | 广东东阳光药业股份有限公司 | 2024-02-15 | — | — | WO | claimed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| CN-117586329-A | Crystalline forms of hepatitis c inhibitors and their use in medicine | 广东东阳光药业股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024032718-A1 | CRYSTAL FORM OF HEPATITIS C INHIBITOR AND USE THEREOF IN DRUG | 广东东阳光药业股份有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-114957366-B | 1, 3-diacetylene lead compound and synthesis method thereof | 康龙化成(宁波)科技发展有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110382514-B | Prodrugs of HCV NS5B polymerase inhibitors and methods of making and using the same | 亚历山大·瓦西里耶维奇·伊瓦切恩科 | 2023-06-02 | — | — | CN | disclosed |
| US-20230020329-A1 | Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof | Ivachtchenko Alexandrovna Alena (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3978503-A1 | ANNELATED 9-HYDROXY-1,8-DIOXO-1,3,4,8-TETRAHYDRO-2H-PYRIDO[1,2-a]PYRAZINE-7-CARBOXAMIDES AS HIV INTEGRASE INHIBITORS | Ivachtchenko, Alena Alexandrovna (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10683315-B2 | Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2020-06-16 | — | — | US | disclosed |
| EP-2808325-B1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | ALLA CHEM LLC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2017-03-09 | — | — | US | disclosed |
| US-9428491-B2 | Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof | ALLA CHEM LLC | 2016-08-30 | — | — | US | disclosed |
| US-9428491-B2 | Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof | ALLA CHEM LLC | 2016-08-30 | — | — | US | disclosed |
| US-9428491-B2 | Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof | ALLA CHEM LLC | 2016-08-30 | — | — | US | disclosed |
| US-20160031859-A1 | Alkyl [(S)-1-((S)-2--buta-1,3-diynyl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate, pharmaceutical composition, medicament, method for treatment of viral diseases | IVASHCHENKO ANDREY ALEXANDROVICH (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2955177-A2 | ALKYL [(S)-1-((S)-2-{5-[4-(4-{2-[(S)-1-((S)-2-METHOXYCARBONYLAMINO-3-METHYL-BUTYRYL)-PYRROLIDINE-2-YL]-3H-IMIDAZOLE-4-YL}-BUTA-1,3-DIENYL)-PHENYL]-1H-IMIDAZOLE-2-YL}-PYRROLIDINE-1-CARBONYL)-2-METHYL-PROPYL]-CARBAMATE NAPHTHALENE-1,5-DISULFONATE, PHARMACEUTICAL COMPOSITION, MEDICINAL AGENT AND METHOD FOR TREATMENT OF VIRAL DISEASES | Ivachtchenko, Alexandre Vasilievich (RU) | 2015-12-16 | — | — | EP | disclosed |
| EP-2808325-A1 | Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof | Alla Chem, LLC. (US) | 2014-12-03 | — | — | EP | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | HCCS, EIF2AK2, HAVCR2 | CYP3A4 20/4885CYP2C9 51/4885KCNH2 3164/4885 |
| US-20170066746-A1 | Pan-genomic inhibitors of NS5A protein encoded by HCV, pharmaceutical compositions, intermediates for inhibitor synthesis, and their synthesis and application methods | POLR2A, GTF3C1, SSU72 | CYP3A4 2186/4885CYP2C9 3009/4885KCNH2 3185/4885 |
| US-20230020329-A1 | Annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamides as HIV integrase inhibitors, methods of preparation and application thereof | CDK9, DPYD, INTS9 | CYP3A4 31/4885CYP2C9 165/4885KCNH2 459/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | CYP3A4 3314/4885CYP2C9 3888/4885KCNH2 1044/4885 |
| US-20160031859-A1 | Alkyl [(S)-1-((S)-2--buta-1,3-diynyl)-phenyl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamate naphthalene-1,5-disulfonate, pharmaceutical composition, medicament, method for treatment of viral diseases | CPS1, CES1, GOT1 | CYP3A4 1749/4885CYP2C9 2185/4885KCNH2 1797/4885 |
| US-10683315-B2 | Prodrug of an HCV NS5B polymerase inhibitor and method of production and application thereof | PNP, CYP7A1, UGT1A1 | CYP3A4 67/4885CYP2C9 36/4885KCNH2 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.